Document 0588
 DOCN  M9590588
 TI    AZT: pediatric study changed after worse monotherapy survival.
       Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231
       ext. 5023.
 DT    9509
 SO    AIDS Treat News. 1995 Feb 17;(no 217):8. Unique Identifier : AIDSLINE
       AIDS/95700330
 AB    The AZT arm of a pediatric study (ACTG 152) was halted early after the
       AZT-treated group showed worse survival than those in at least one of
       the comparison treatment groups. The double-blind study treated patients
       with either AZT alone, AZT with ddI, or ddI alone. The study is
       continuing with ddI and the AZT/ddI combination. The AZT monotherapy
       results were unexpected and the reasons are currently unknown. One
       question of interest is the effect of age on the outcomes. It is
       believed age-related analysis will be important for developing treatment
       recommendations for children of different ages, for understanding what
       this result may mean in terms of treating adults, and for guidance about
       when and how adult data can reliably be used to guide treatment for
       children.
 DE    Adolescence  Child  Child, Preschool  Didanosine/ADMINISTRATION &
       DOSAGE/THERAPEUTIC USE  Drug Therapy, Combination  HIV Infections/*DRUG
       THERAPY/MORTALITY  Human  Infant  Survival Analysis
       Zidovudine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  NEWSLETTER ARTICLE
       RANDOMIZED CONTROLLED TRIAL  CLINICAL TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).